View Future GrowthArcticZymes Technologies 過去の業績過去 基準チェック /46ArcticZymes Technologiesの収益は年間平均-49.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.3% 2.9%割合で 減少しています。 ArcticZymes Technologiesの自己資本利益率は3.9%であり、純利益率は10.5%です。主要情報-49.94%収益成長率-50.88%EPS成長率Biotechs 業界の成長-14.59%収益成長率-2.86%株主資本利益率3.95%ネット・マージン10.46%次回の業績アップデート14 Aug 2026最近の業績更新お知らせ • Dec 19+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2026 Results on May 07, 2026ArcticZymes Technologies ASA announced that they will report Q1, 2026 results on May 07, 2026お知らせ • Dec 03+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2025 Results on May 08, 2025ArcticZymes Technologies ASA announced that they will report Q1, 2025 results on May 08, 2025Reported Earnings • Nov 07Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.12 profit in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (down from kr0.12 profit in 3Q 2023). Revenue: kr24.1m (down 23% from 3Q 2023). Net loss: kr1.56m (down 126% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 51% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023)Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.Reported Earnings • May 09First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr30.0m (down 3.8% from 1Q 2023). Net income: kr3.17m (down 37% from 1Q 2023). Profit margin: 11% (down from 16% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022)Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.すべての更新を表示Recent updatesNew Risk • 6hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (€87.5m market cap, or US$99.8m).お知らせ • May 02Arcticzymes Technologies Asa Strengthens Ip Platform with New Patent Grant Supporting Expansion into Rna Therapeutics ManufacturingArcticZymes Technologies ASA announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company's strategic expansion into the rapidly growing RNA therapeutics manufacturing market. The newly granted patent strengthens ArcticZymes' proprietary technology platform with the introduction of a novel RNA restriction enzyme family focused on enabling analytical, process development and manufacturing workflows for therapeutic RNA production. The protection covers key application areas relevant to RNA processing, quality control and scalable manufacturing workflows. The global RNA therapeutics market continues to expand, driven by increasing clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel modalities. As programmes progress toward late-stage development and commercialisation, demand is rising for robust, scalable and IP-secure manufacturing technologies that can improve process efficiency, product quality and regulatory confidence. ArcticZymes expects the protected technology to strengthen ongoing business development discussions with prospective partners and customers active in RNA therapeutics manufacturing. ArcticZymes will continue investing in internal innovation, targeted IP creation and strategic collaborations to expand its presence in high-growth biomanufacturing segments. ArcticZymes believes RNA therapeutics represents a significant long-term growth opportunity and remains committed to building a differentiated portfolio of enabling technologies to serve this expanding market.お知らせ • Dec 20ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026.お知らせ • Dec 19+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2026 Results on May 07, 2026ArcticZymes Technologies ASA announced that they will report Q1, 2026 results on May 07, 2026お知らせ • Dec 09ArcticZymes Technologies ASA Expands San HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine BiomanufacturersArcticZymes Technologies introduced two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector. The new SAN HQ ELISA Senso Plus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as a reusable format, reduced assay execution times, and lower costs make it an invaluable tool for streamlining biomanufacturing operations. Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects ArcticZymes' commitment to expanding its portfolio of high-performance nucleases, providing biomanufacturers the flexibility to select solutions tailored to their unique production needs. By adding GMP variants to its portfolio, ArcticZymes is proactively addressing the increasingly stringent regulatory requirements of the biomanufacturing industry, enabling partners to achieve compliance with global standards while optimizing their production processes.お知らせ • Dec 04ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025.お知らせ • Dec 03+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2025 Results on May 08, 2025ArcticZymes Technologies ASA announced that they will report Q1, 2025 results on May 08, 2025Reported Earnings • Nov 07Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.12 profit in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (down from kr0.12 profit in 3Q 2023). Revenue: kr24.1m (down 23% from 3Q 2023). Net loss: kr1.56m (down 126% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 51% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.15, the stock trades at a forward P/E ratio of 32x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 87% over the past three years.Valuation Update With 7 Day Price Move • Sep 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €1.38, the stock trades at a forward P/E ratio of 34x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.New Risk • Aug 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.4m (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€88.4m market cap, or US$98.9m).New Risk • Aug 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023)Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.お知らせ • Jul 31ArcticZymes Technologies ASA Announces the Appointment of Frank Mathias as Chairman of the Board of DirectorsOxford Biomedica plc announced that Dr. Frank Mathias, Chief Executive Officer, has been appointed as Chairman of the Board of Directors of ArcticZymes Technologies ASA.Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €2.21, the stock trades at a forward P/E ratio of 58x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.30 per share.New Risk • May 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 28% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (28% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin).Board Change • May 15Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jane Theaker was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14ArcticZymes Technologies ASA Announces Board ResignationsArcticZymes Technologies ASA announced changes to its governance structure. The Election committee has proposed changes to the Board to guide and strengthen the strategic and commercial development of the company. Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately. During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating ArcticZymes into a globally profitable player in the life science tools sector. Her leadership laid a robust foundation for long-term growth, for which the Election committee extends its sincere appreciation. Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The committee acknowledges Mrs. Theaker's valuable contributions and thanks her for her service.Reported Earnings • May 09First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr30.0m (down 3.8% from 1Q 2023). Net income: kr3.17m (down 37% from 1Q 2023). Profit margin: 11% (down from 16% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.お知らせ • Apr 02ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board MemberArcticZymes Technologies ASA announced Board member Edgar Koster has informed the board that he will resign from the board with immediate effect for personal reasons.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment deteriorates as stock falls 33%After last week's 33% share price decline to €2.36, the stock trades at a forward P/E ratio of 72x. Average trailing P/E is 33x in the Biotechs industry in Europe. Total loss to shareholders of 61% over the past three years.New Risk • Feb 07New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin).Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022)Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Jan 30Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San HqArcticZymes Technologies ASA announced the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). SAN HQ GMP from ArcticZymes offers a technically superior solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio to include a GMP-grade nuclease. ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced therapies sector. To streamline the supplier and material qualification process and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves as a superior solution. The inclusion of a US FDA DMF further facilitates regulatory submission. SAN HQ GMP not only offers a technically superior option for enzymatic applications and provides a more straightforward supplier qualification process for customers. By reducing risks and minimizing resource expenditure on external product qualification, the new SAN HQ GMP ensures that clients in the pharmaceutical industry can access the most cutting-edge solution without compromising on compliance. The new SAN HQ GMP will be available for ordering in the second half of February 2024.お知らせ • Dec 21ArcticZymes Technologies ASA Launches T7 RNA PolymeraseArcticZymes Technologies ASA announced the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is rapidly evolving, the T7 RNA Polymerase may support different research areas as well as being a key component in various molecular diagnostic applications. The T7 RNA Polymerase will be available for ordering during January 2024.お知らせ • Dec 14+ 5 more updatesArcticZymes Technologies ASA, Annual General Meeting, Jun 05, 2024ArcticZymes Technologies ASA, Annual General Meeting, Jun 05, 2024.Reported Earnings • Nov 03Third quarter 2023 earnings released: EPS: kr0.12 (vs kr0.05 in 3Q 2022)Third quarter 2023 results: EPS: kr0.12 (up from kr0.05 in 3Q 2022). Revenue: kr31.2m (up 4.9% from 3Q 2022). Net income: kr6.06m (up 143% from 3Q 2022). Profit margin: 20% (up from 8.4% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.New Risk • Nov 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (12% net profit margin).お知らせ • Sep 21ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDAArcticZymes Technologies ASA announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers with a Letter of Authorization (LoA) for their product registrations with the US FDA upon request. AZT anticipates commercial launch of SAN HQ GMP in Fourth Quarter 2023.Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.17 in 2Q 2022)Second quarter 2023 results: EPS: kr0.11 (down from kr0.17 in 2Q 2022). Revenue: kr28.2m (down 7.0% from 2Q 2022). Net income: kr5.60m (down 36% from 2Q 2022). Profit margin: 20% (down from 29% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Jul 17ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023ArcticZymes Technologies ASA announced the appointment of Michael Akoh as its new Chief Executive Officer. Michael is an accomplished business executive with strong leadership experience, and an established reputation in the life sciences sector. He has over 20+ years of international experience in general management, business development and commercialization within the biopharma industry, including senior roles at diagnostic, med tech and CRO companies. Michael holds a BSc. (Econ) and a MSc. in International Marketing and Management from the Copenhagen Business School. Michael will commence his position no later than 1 November 2023.Reported Earnings • May 05First quarter 2023 earnings released: EPS: kr0.10 (vs kr0.41 in 1Q 2022)First quarter 2023 results: EPS: kr0.10 (down from kr0.41 in 1Q 2022). Revenue: kr31.2m (down 37% from 1Q 2022). Net income: kr5.04m (down 76% from 1Q 2022). Profit margin: 16% (down from 42% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.Reported Earnings • Feb 04Full year 2022 earnings released: EPS: kr0.65 (vs kr0.94 in FY 2021)Full year 2022 results: EPS: kr0.65 (down from kr0.94 in FY 2021). Revenue: kr137.7m (up 5.0% from FY 2021). Net income: kr33.1m (down 29% from FY 2021). Profit margin: 24% (down from 35% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to €5.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 973% over the past three years.お知らせ • Dec 21ArcticZymes Technologies Launches SAN HQ 2.0 ELISA kitArcticZymes Technologies announced the launch of the SAN HQ 2.0 ELISA kit. The SAN HQ 2.0 ELISA kit is intended as a natural companion product to already successful Salt Active Nuclease - SAN HQ 2.0. The new ELISA product is a classic sandwich immunoassay designed to detect and quantify the presence of the SAN HQ 2.0 nuclease at trace amounts. Customers working with bioprocessing workflows will be able to use SAN HQ 2.0 to remove contaminating nucleic acids, and then verify the removal of the nuclease using the SAN HQ 2.0 ELISA kit after downstream processing and purification. This is important as all processing agents, used during biomanufacturing processes leading to human therapeutic agents, are subject to tight controls with respect to residual amounts present in the final formulation. Quantification is critical, therefore the enzyme SAN HQ 2.0 and the new SAN HQ 2.0 ELISA kit are complementary products. The new ELISA kit will further accelerate the adoption of SAN HQ 2.0 in customers' bioprocessing workflows. The global biomanufacturing market has seen significant growth in recent years, in part due to a boom in cell and gene therapy development, and the high demand for vaccine manufacturing during the Coronavirus pandemic. Providing customers with more complete solutions, such as processing enzymes and corresponding immunoassay kits, will be an important driver to continued sales growth in the biomanufacturing business.お知らせ • Dec 02ArcticZymes Technologies ASA Appoints Darren Ellis as Chief Scientific OfficerArcticZymes Technologies has appointed Dr. Darren Ellis as its first Chief Scientific Officer. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and ThermoFisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies and products. Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners and customers to bring their technologies and product developments tomarket. Dr. Ellis joined the Company in March this year to lead the establishment of the Application Laboratory at Oslo Science Park and to recruit an experienced team of application scientists. The laboratory is operational and currently focusing on the development of workflow applications related to infectious disease testing. As CSO, Dr. Ellis will support the Company to strategically expand and optimize the Company´s innovation capabilities and efforts in Norway and internationally as the Company grows both organically and inorganically. He will lead an international and experienced scientific team with the ability to bring further cutting edge and high-value innovations to market, hence, elevating theinnovation pipeline to the next level.お知らせ • Nov 26+ 5 more updatesArcticZymes Technologies ASA to Report Q4, 2022 Results on Feb 02, 2023ArcticZymes Technologies ASA announced that they will report Q4, 2022 results on Feb 02, 2023Board Change • Nov 16No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: kr0.05 (vs kr0.14 in 3Q 2021)Third quarter 2022 results: EPS: kr0.05 (down from kr0.14 in 3Q 2021). Revenue: kr29.7m (up 12% from 3Q 2021). Net income: kr2.49m (down 64% from 3Q 2021). Profit margin: 8.4% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 25ArcticZymes Technologies ASA Announces Resignation of Volker Wedershoven as Board MemberArcticZymes Technologies ASA announced its Board member Volker Wedershoven has informed the board that he will resign from the board with immediate effect for personal reasons. The remaining board complies with the requirements regarding board composition and will still constitute a quorum.Reported Earnings • Aug 19Second quarter 2022 earnings released: EPS: kr0.17 (vs kr0.09 in 2Q 2021)Second quarter 2022 results: EPS: kr0.17 (up from kr0.09 in 2Q 2021). Revenue: kr30.3m (up 35% from 2Q 2021). Net income: kr8.75m (up 86% from 2Q 2021). Profit margin: 29% (up from 21% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 158% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: kr0.41 (vs kr0.40 in 1Q 2021)First quarter 2022 results: EPS: kr0.41 (up from kr0.40 in 1Q 2021). Revenue: kr49.2m (up 20% from 1Q 2021). Net income: kr20.8m (up 7.5% from 1Q 2021). Profit margin: 42% (down from 47% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 23%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr0.92 (down from kr1.53 in FY 2020). Revenue: kr131.0m (up 34% from FY 2020). Net income: kr46.2m (down 37% from FY 2020). Profit margin: 35% (down from 75% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.8%. Over the next year, revenue is forecast to grow 20%, compared to a 68% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has increased by 175% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 28ArcticZymes Technologies ASA Provides Sales Guidance for the Year 2022ArcticZymes Technologies ASA provided sales guidance for the year 2022. For the year, the company expects topline sales growth with an annual sales target of NOK 155 million.お知らせ • Dec 22ArcticZymes Technologies Launches New ProductsArcticZymes technologies announced the launch of following new products: ArcticZymes R2DTM Ligase - Patent pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is an enabling tool for new technology development and is expected to have broad applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS), and gene/RNA synthesis applications for potential therapeutic applications. IsoPol® BST+ High Concentration Glycerol FREE - highly concentrated formulation of the DNA polymerase to support ongoing customer opportunities for utility in new NGS platform technologies and Point-of-Care diagnostic test developments. M-SAN HQ ELISAkit - The new ELISA immunoassay product is an essential support product for customers using the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. In combination with the M-SAN HQ enzyme, the new immunoassay product provides a complete solution for the critical elimination of DNA contamination during biomanufacturing. M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing process has been upscaled and transitioned to large-scale fermentation. This successful upscaling achieved greater than a 100-fold increase in fermentation yield. The upscaling was necessary to meet the expected increase in demand following the launch of the ELISA kit and ensure customers can receive large quantities of enzyme from a single production batch. The ArcticZymes R2DTM Ligase and M-SAN HQ products will be available in its warehouses during January 2022. The IsoPol® BST+ High Concentration Glycerol FREE product will be available during February 2022.Recent Insider Transactions • Dec 12Chief Executive Officer recently sold €1.0m worth of stockOn the 10th of December, Jethro Holter sold around 120k shares on-market at roughly €8.68 per share. This was the largest sale by an insider in the last 3 months. This was Jethro's only on-market trade for the last 12 months.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.14 (vs kr0.19 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr26.4m (down 16% from 3Q 2020). Net income: kr6.89m (down 24% from 3Q 2020). Profit margin: 26% (down from 29% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has increased by 177% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS kr0.09 (vs kr0.44 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr22.4m (down 34% from 2Q 2020). Net income: kr4.70m (down 78% from 2Q 2020). Profit margin: 21% (down from 63% in 2Q 2020). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to kr7.60, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 22x in the Biotechs industry in Europe. Total returns to shareholders of 1,392% over the past three years.お知らせ • Jun 30ArcticZymes Technologies ASA Launches SAN HQ 2.0ArcticZymes Technologies ASA announced the launch of the second generation of its SAN HQ enzyme. ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme has achieved significant penetration in the viral vector manufacturing space in the last 5 years. Viral vectors are used in therapeutic applications such as vaccines and gene therapies. SAN HQ treatment is used in the downstream purification of viral vectors to remove contaminating DNA. The second generation of the enzyme, SAN HQ 2.0, has been optimised for wider compatibility with downstream processes used in biomanufacturing. In particular, SAN HQ 2.0 offers improved resolution in several chromatographic techniques, thereby simplifying the separation of the nuclease from the target product post treatment. ArcticZymes anticipates that SAN HQ 2.0 will increase the Company's reach within the viral vector space and provide new opportunities in recombinant protein production. The product will be commercially available from late third quarter 2021.Recent Insider Transactions • May 20Director recently sold €170k worth of stockOn the 18th of May, Volker Wedershoven sold around 20k shares on-market at roughly €8.49 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to kr9.66, the stock trades at a trailing P/E ratio of 54.8x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 1,509% over the past three years.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.40 (vs kr0.28 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr41.0m (up 15% from 1Q 2020). Net income: kr19.4m (up 41% from 1Q 2020). Profit margin: 47% (up from 39% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Mar 03New 90-day high: €8.10The company is up 27% from its price of €6.38 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to kr5.82, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 47.1x. This compares to an average P/E of 41x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 767%.Reported Earnings • Jan 30Full year 2020 earnings released: EPS kr1.75 (vs kr0.13 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr97.8m (up 16% from FY 2019). Net income: kr75.4m (up kr81.8m from FY 2019). Profit margin: 77% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 26ArcticZymes Technologies ASA to Report Q4, 2020 Results on Jan 28, 2021ArcticZymes Technologies ASA announced that they will report Q4, 2020 results at 7:00 AM, Central European Standard Time on Jan 28, 2021Is New 90 Day High Low • Jan 22New 90-day high: €7.74The company is up 31% from its price of €5.92 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr7.02, the stock is trading at a trailing P/E ratio of 73.4x, up from the previous P/E ratio of 60.8x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 841%.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to kr6.68, the stock is trading at a trailing P/E ratio of 71.8x, up from the previous P/E ratio of 62.3x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 826%.Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 16% share price gain to kr5.64, the stock is trading at a trailing P/E ratio of 60x, up from the previous P/E ratio of 51.9x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 636%.Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 33% share price decline to kr4.89, the stock is trading at a trailing P/E ratio of 52.6x, down from the previous P/E ratio of 78.9x. This compares to an average P/E of 33x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 533%.Is New 90 Day High Low • Oct 07New 90-day high: €6.60The company is up 67% from its price of €3.96 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period.お知らせ • Sep 23ArcticZymes Technologies ASA to Report Q3, 2020 Results on Oct 22, 2020ArcticZymes Technologies ASA announced that they will report Q3, 2020 results on Oct 22, 2020お知らせ • Aug 14ArcticZymes Technologies ASA to Report Q2, 2020 Results on Aug 19, 2020ArcticZymes Technologies ASA announced that they will report Q2, 2020 results at 7:00 AM, Central European Standard Time on Aug 19, 2020収支内訳ArcticZymes Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:B4V 収益、費用、利益 ( )NOK Millions日付収益収益G+A経費研究開発費31 Mar 261281372031 Dec 251181070030 Sep 25110765030 Jun 25104363031 Mar 25103262031 Dec 24108862030 Sep 24111564030 Jun 241181363031 Mar 241181863031 Dec 231201961030 Sep 231192060030 Jun 231181664031 Mar 231201763031 Dec 221383361030 Sep 221504759030 Jun 221475252031 Mar 221394852031 Dec 211314648030 Sep 211146845030 Jun 211086743031 Mar 211208437031 Dec 20987435030 Sep 20644327030 Jun 20683729031 Mar 2088846031 Dec 1949-134030 Sep 1980-949030 Jun 1979-1047031 Mar 1973-1347031 Dec 1873-1446030 Sep 1870-2049030 Jun 1863-2750031 Mar 1869-2751031 Dec 1773-2552030 Sep 1774-2659030 Jun 1780-2458031 Mar 1779-2157031 Dec 1679-2057030 Sep 1678-2053030 Jun 1672-1951031 Mar 1666-1849031 Dec 1559-1747030 Sep 1555-15420質の高い収益: B4Vは 高品質の収益 を持っています。利益率の向上: B4Vの現在の純利益率 (10.5%)は、昨年(2.1%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: B4Vの収益は過去 5 年間で年間49.9%減少しました。成長の加速: B4Vの過去 1 年間の収益成長率 ( 512.8% ) は、5 年間の平均 ( 年間-49.9%を上回っています。収益対業界: B4Vの過去 1 年間の収益成長率 ( 512.8% ) はBiotechs業界1.2%を上回りました。株主資本利益率高いROE: B4Vの 自己資本利益率 ( 3.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 04:03終値2026/07/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ArcticZymes Technologies ASA 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Mikkel Nyholt-SmedsengCarnegie Investment Bank ABEspen JørgensenDNB CarnegieViktor SundbergNordea Markets3 その他のアナリストを表示
お知らせ • Dec 19+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2026 Results on May 07, 2026ArcticZymes Technologies ASA announced that they will report Q1, 2026 results on May 07, 2026
お知らせ • Dec 03+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2025 Results on May 08, 2025ArcticZymes Technologies ASA announced that they will report Q1, 2025 results on May 08, 2025
Reported Earnings • Nov 07Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.12 profit in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (down from kr0.12 profit in 3Q 2023). Revenue: kr24.1m (down 23% from 3Q 2023). Net loss: kr1.56m (down 126% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 51% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023)Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 09First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr30.0m (down 3.8% from 1Q 2023). Net income: kr3.17m (down 37% from 1Q 2023). Profit margin: 11% (down from 16% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022)Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
New Risk • 6hNew minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €87.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (€87.5m market cap, or US$99.8m).
お知らせ • May 02Arcticzymes Technologies Asa Strengthens Ip Platform with New Patent Grant Supporting Expansion into Rna Therapeutics ManufacturingArcticZymes Technologies ASA announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company's strategic expansion into the rapidly growing RNA therapeutics manufacturing market. The newly granted patent strengthens ArcticZymes' proprietary technology platform with the introduction of a novel RNA restriction enzyme family focused on enabling analytical, process development and manufacturing workflows for therapeutic RNA production. The protection covers key application areas relevant to RNA processing, quality control and scalable manufacturing workflows. The global RNA therapeutics market continues to expand, driven by increasing clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel modalities. As programmes progress toward late-stage development and commercialisation, demand is rising for robust, scalable and IP-secure manufacturing technologies that can improve process efficiency, product quality and regulatory confidence. ArcticZymes expects the protected technology to strengthen ongoing business development discussions with prospective partners and customers active in RNA therapeutics manufacturing. ArcticZymes will continue investing in internal innovation, targeted IP creation and strategic collaborations to expand its presence in high-growth biomanufacturing segments. ArcticZymes believes RNA therapeutics represents a significant long-term growth opportunity and remains committed to building a differentiated portfolio of enabling technologies to serve this expanding market.
お知らせ • Dec 20ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026.
お知らせ • Dec 19+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2026 Results on May 07, 2026ArcticZymes Technologies ASA announced that they will report Q1, 2026 results on May 07, 2026
お知らせ • Dec 09ArcticZymes Technologies ASA Expands San HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine BiomanufacturersArcticZymes Technologies introduced two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector. The new SAN HQ ELISA Senso Plus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as a reusable format, reduced assay execution times, and lower costs make it an invaluable tool for streamlining biomanufacturing operations. Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects ArcticZymes' commitment to expanding its portfolio of high-performance nucleases, providing biomanufacturers the flexibility to select solutions tailored to their unique production needs. By adding GMP variants to its portfolio, ArcticZymes is proactively addressing the increasingly stringent regulatory requirements of the biomanufacturing industry, enabling partners to achieve compliance with global standards while optimizing their production processes.
お知らせ • Dec 04ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025.
お知らせ • Dec 03+ 4 more updatesArcticZymes Technologies ASA to Report Q1, 2025 Results on May 08, 2025ArcticZymes Technologies ASA announced that they will report Q1, 2025 results on May 08, 2025
Reported Earnings • Nov 07Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.12 profit in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (down from kr0.12 profit in 3Q 2023). Revenue: kr24.1m (down 23% from 3Q 2023). Net loss: kr1.56m (down 126% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 51% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €1.15, the stock trades at a forward P/E ratio of 32x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 87% over the past three years.
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €1.38, the stock trades at a forward P/E ratio of 34x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years.
New Risk • Aug 27New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.4m (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€88.4m market cap, or US$98.9m).
New Risk • Aug 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023)Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 31ArcticZymes Technologies ASA Announces the Appointment of Frank Mathias as Chairman of the Board of DirectorsOxford Biomedica plc announced that Dr. Frank Mathias, Chief Executive Officer, has been appointed as Chairman of the Board of Directors of ArcticZymes Technologies ASA.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €2.21, the stock trades at a forward P/E ratio of 58x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.30 per share.
New Risk • May 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 28% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (28% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin).
Board Change • May 15Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jane Theaker was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14ArcticZymes Technologies ASA Announces Board ResignationsArcticZymes Technologies ASA announced changes to its governance structure. The Election committee has proposed changes to the Board to guide and strengthen the strategic and commercial development of the company. Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately. During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating ArcticZymes into a globally profitable player in the life science tools sector. Her leadership laid a robust foundation for long-term growth, for which the Election committee extends its sincere appreciation. Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The committee acknowledges Mrs. Theaker's valuable contributions and thanks her for her service.
Reported Earnings • May 09First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr30.0m (down 3.8% from 1Q 2023). Net income: kr3.17m (down 37% from 1Q 2023). Profit margin: 11% (down from 16% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 02ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board MemberArcticZymes Technologies ASA announced Board member Edgar Koster has informed the board that he will resign from the board with immediate effect for personal reasons.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment deteriorates as stock falls 33%After last week's 33% share price decline to €2.36, the stock trades at a forward P/E ratio of 72x. Average trailing P/E is 33x in the Biotechs industry in Europe. Total loss to shareholders of 61% over the past three years.
New Risk • Feb 07New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin).
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022)Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 30Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San HqArcticZymes Technologies ASA announced the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). SAN HQ GMP from ArcticZymes offers a technically superior solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio to include a GMP-grade nuclease. ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced therapies sector. To streamline the supplier and material qualification process and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves as a superior solution. The inclusion of a US FDA DMF further facilitates regulatory submission. SAN HQ GMP not only offers a technically superior option for enzymatic applications and provides a more straightforward supplier qualification process for customers. By reducing risks and minimizing resource expenditure on external product qualification, the new SAN HQ GMP ensures that clients in the pharmaceutical industry can access the most cutting-edge solution without compromising on compliance. The new SAN HQ GMP will be available for ordering in the second half of February 2024.
お知らせ • Dec 21ArcticZymes Technologies ASA Launches T7 RNA PolymeraseArcticZymes Technologies ASA announced the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is rapidly evolving, the T7 RNA Polymerase may support different research areas as well as being a key component in various molecular diagnostic applications. The T7 RNA Polymerase will be available for ordering during January 2024.
お知らせ • Dec 14+ 5 more updatesArcticZymes Technologies ASA, Annual General Meeting, Jun 05, 2024ArcticZymes Technologies ASA, Annual General Meeting, Jun 05, 2024.
Reported Earnings • Nov 03Third quarter 2023 earnings released: EPS: kr0.12 (vs kr0.05 in 3Q 2022)Third quarter 2023 results: EPS: kr0.12 (up from kr0.05 in 3Q 2022). Revenue: kr31.2m (up 4.9% from 3Q 2022). Net income: kr6.06m (up 143% from 3Q 2022). Profit margin: 20% (up from 8.4% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
New Risk • Nov 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (12% net profit margin).
お知らせ • Sep 21ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDAArcticZymes Technologies ASA announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers with a Letter of Authorization (LoA) for their product registrations with the US FDA upon request. AZT anticipates commercial launch of SAN HQ GMP in Fourth Quarter 2023.
Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.17 in 2Q 2022)Second quarter 2023 results: EPS: kr0.11 (down from kr0.17 in 2Q 2022). Revenue: kr28.2m (down 7.0% from 2Q 2022). Net income: kr5.60m (down 36% from 2Q 2022). Profit margin: 20% (down from 29% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 17ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023ArcticZymes Technologies ASA announced the appointment of Michael Akoh as its new Chief Executive Officer. Michael is an accomplished business executive with strong leadership experience, and an established reputation in the life sciences sector. He has over 20+ years of international experience in general management, business development and commercialization within the biopharma industry, including senior roles at diagnostic, med tech and CRO companies. Michael holds a BSc. (Econ) and a MSc. in International Marketing and Management from the Copenhagen Business School. Michael will commence his position no later than 1 November 2023.
Reported Earnings • May 05First quarter 2023 earnings released: EPS: kr0.10 (vs kr0.41 in 1Q 2022)First quarter 2023 results: EPS: kr0.10 (down from kr0.41 in 1Q 2022). Revenue: kr31.2m (down 37% from 1Q 2022). Net income: kr5.04m (down 76% from 1Q 2022). Profit margin: 16% (down from 42% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 04Full year 2022 earnings released: EPS: kr0.65 (vs kr0.94 in FY 2021)Full year 2022 results: EPS: kr0.65 (down from kr0.94 in FY 2021). Revenue: kr137.7m (up 5.0% from FY 2021). Net income: kr33.1m (down 29% from FY 2021). Profit margin: 24% (down from 35% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to €5.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 973% over the past three years.
お知らせ • Dec 21ArcticZymes Technologies Launches SAN HQ 2.0 ELISA kitArcticZymes Technologies announced the launch of the SAN HQ 2.0 ELISA kit. The SAN HQ 2.0 ELISA kit is intended as a natural companion product to already successful Salt Active Nuclease - SAN HQ 2.0. The new ELISA product is a classic sandwich immunoassay designed to detect and quantify the presence of the SAN HQ 2.0 nuclease at trace amounts. Customers working with bioprocessing workflows will be able to use SAN HQ 2.0 to remove contaminating nucleic acids, and then verify the removal of the nuclease using the SAN HQ 2.0 ELISA kit after downstream processing and purification. This is important as all processing agents, used during biomanufacturing processes leading to human therapeutic agents, are subject to tight controls with respect to residual amounts present in the final formulation. Quantification is critical, therefore the enzyme SAN HQ 2.0 and the new SAN HQ 2.0 ELISA kit are complementary products. The new ELISA kit will further accelerate the adoption of SAN HQ 2.0 in customers' bioprocessing workflows. The global biomanufacturing market has seen significant growth in recent years, in part due to a boom in cell and gene therapy development, and the high demand for vaccine manufacturing during the Coronavirus pandemic. Providing customers with more complete solutions, such as processing enzymes and corresponding immunoassay kits, will be an important driver to continued sales growth in the biomanufacturing business.
お知らせ • Dec 02ArcticZymes Technologies ASA Appoints Darren Ellis as Chief Scientific OfficerArcticZymes Technologies has appointed Dr. Darren Ellis as its first Chief Scientific Officer. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and ThermoFisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies and products. Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners and customers to bring their technologies and product developments tomarket. Dr. Ellis joined the Company in March this year to lead the establishment of the Application Laboratory at Oslo Science Park and to recruit an experienced team of application scientists. The laboratory is operational and currently focusing on the development of workflow applications related to infectious disease testing. As CSO, Dr. Ellis will support the Company to strategically expand and optimize the Company´s innovation capabilities and efforts in Norway and internationally as the Company grows both organically and inorganically. He will lead an international and experienced scientific team with the ability to bring further cutting edge and high-value innovations to market, hence, elevating theinnovation pipeline to the next level.
お知らせ • Nov 26+ 5 more updatesArcticZymes Technologies ASA to Report Q4, 2022 Results on Feb 02, 2023ArcticZymes Technologies ASA announced that they will report Q4, 2022 results on Feb 02, 2023
Board Change • Nov 16No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: kr0.05 (vs kr0.14 in 3Q 2021)Third quarter 2022 results: EPS: kr0.05 (down from kr0.14 in 3Q 2021). Revenue: kr29.7m (up 12% from 3Q 2021). Net income: kr2.49m (down 64% from 3Q 2021). Profit margin: 8.4% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 25ArcticZymes Technologies ASA Announces Resignation of Volker Wedershoven as Board MemberArcticZymes Technologies ASA announced its Board member Volker Wedershoven has informed the board that he will resign from the board with immediate effect for personal reasons. The remaining board complies with the requirements regarding board composition and will still constitute a quorum.
Reported Earnings • Aug 19Second quarter 2022 earnings released: EPS: kr0.17 (vs kr0.09 in 2Q 2021)Second quarter 2022 results: EPS: kr0.17 (up from kr0.09 in 2Q 2021). Revenue: kr30.3m (up 35% from 2Q 2021). Net income: kr8.75m (up 86% from 2Q 2021). Profit margin: 29% (up from 21% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 158% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: kr0.41 (vs kr0.40 in 1Q 2021)First quarter 2022 results: EPS: kr0.41 (up from kr0.40 in 1Q 2021). Revenue: kr49.2m (up 20% from 1Q 2021). Net income: kr20.8m (up 7.5% from 1Q 2021). Profit margin: 42% (down from 47% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 23%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr0.92 (down from kr1.53 in FY 2020). Revenue: kr131.0m (up 34% from FY 2020). Net income: kr46.2m (down 37% from FY 2020). Profit margin: 35% (down from 75% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.8%. Over the next year, revenue is forecast to grow 20%, compared to a 68% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has increased by 175% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 28ArcticZymes Technologies ASA Provides Sales Guidance for the Year 2022ArcticZymes Technologies ASA provided sales guidance for the year 2022. For the year, the company expects topline sales growth with an annual sales target of NOK 155 million.
お知らせ • Dec 22ArcticZymes Technologies Launches New ProductsArcticZymes technologies announced the launch of following new products: ArcticZymes R2DTM Ligase - Patent pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is an enabling tool for new technology development and is expected to have broad applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS), and gene/RNA synthesis applications for potential therapeutic applications. IsoPol® BST+ High Concentration Glycerol FREE - highly concentrated formulation of the DNA polymerase to support ongoing customer opportunities for utility in new NGS platform technologies and Point-of-Care diagnostic test developments. M-SAN HQ ELISAkit - The new ELISA immunoassay product is an essential support product for customers using the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. In combination with the M-SAN HQ enzyme, the new immunoassay product provides a complete solution for the critical elimination of DNA contamination during biomanufacturing. M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing process has been upscaled and transitioned to large-scale fermentation. This successful upscaling achieved greater than a 100-fold increase in fermentation yield. The upscaling was necessary to meet the expected increase in demand following the launch of the ELISA kit and ensure customers can receive large quantities of enzyme from a single production batch. The ArcticZymes R2DTM Ligase and M-SAN HQ products will be available in its warehouses during January 2022. The IsoPol® BST+ High Concentration Glycerol FREE product will be available during February 2022.
Recent Insider Transactions • Dec 12Chief Executive Officer recently sold €1.0m worth of stockOn the 10th of December, Jethro Holter sold around 120k shares on-market at roughly €8.68 per share. This was the largest sale by an insider in the last 3 months. This was Jethro's only on-market trade for the last 12 months.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr0.14 (vs kr0.19 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr26.4m (down 16% from 3Q 2020). Net income: kr6.89m (down 24% from 3Q 2020). Profit margin: 26% (down from 29% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has increased by 177% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 22Second quarter 2021 earnings released: EPS kr0.09 (vs kr0.44 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr22.4m (down 34% from 2Q 2020). Net income: kr4.70m (down 78% from 2Q 2020). Profit margin: 21% (down from 63% in 2Q 2020). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to kr7.60, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 22x in the Biotechs industry in Europe. Total returns to shareholders of 1,392% over the past three years.
お知らせ • Jun 30ArcticZymes Technologies ASA Launches SAN HQ 2.0ArcticZymes Technologies ASA announced the launch of the second generation of its SAN HQ enzyme. ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme has achieved significant penetration in the viral vector manufacturing space in the last 5 years. Viral vectors are used in therapeutic applications such as vaccines and gene therapies. SAN HQ treatment is used in the downstream purification of viral vectors to remove contaminating DNA. The second generation of the enzyme, SAN HQ 2.0, has been optimised for wider compatibility with downstream processes used in biomanufacturing. In particular, SAN HQ 2.0 offers improved resolution in several chromatographic techniques, thereby simplifying the separation of the nuclease from the target product post treatment. ArcticZymes anticipates that SAN HQ 2.0 will increase the Company's reach within the viral vector space and provide new opportunities in recombinant protein production. The product will be commercially available from late third quarter 2021.
Recent Insider Transactions • May 20Director recently sold €170k worth of stockOn the 18th of May, Volker Wedershoven sold around 20k shares on-market at roughly €8.49 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to kr9.66, the stock trades at a trailing P/E ratio of 54.8x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 1,509% over the past three years.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS kr0.40 (vs kr0.28 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr41.0m (up 15% from 1Q 2020). Net income: kr19.4m (up 41% from 1Q 2020). Profit margin: 47% (up from 39% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Mar 03New 90-day high: €8.10The company is up 27% from its price of €6.38 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to kr5.82, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 47.1x. This compares to an average P/E of 41x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 767%.
Reported Earnings • Jan 30Full year 2020 earnings released: EPS kr1.75 (vs kr0.13 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr97.8m (up 16% from FY 2019). Net income: kr75.4m (up kr81.8m from FY 2019). Profit margin: 77% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 26ArcticZymes Technologies ASA to Report Q4, 2020 Results on Jan 28, 2021ArcticZymes Technologies ASA announced that they will report Q4, 2020 results at 7:00 AM, Central European Standard Time on Jan 28, 2021
Is New 90 Day High Low • Jan 22New 90-day high: €7.74The company is up 31% from its price of €5.92 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 21% share price gain to kr7.02, the stock is trading at a trailing P/E ratio of 73.4x, up from the previous P/E ratio of 60.8x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 841%.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 15% share price gain to kr6.68, the stock is trading at a trailing P/E ratio of 71.8x, up from the previous P/E ratio of 62.3x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 826%.
Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 16% share price gain to kr5.64, the stock is trading at a trailing P/E ratio of 60x, up from the previous P/E ratio of 51.9x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 636%.
Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 33% share price decline to kr4.89, the stock is trading at a trailing P/E ratio of 52.6x, down from the previous P/E ratio of 78.9x. This compares to an average P/E of 33x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 533%.
Is New 90 Day High Low • Oct 07New 90-day high: €6.60The company is up 67% from its price of €3.96 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period.
お知らせ • Sep 23ArcticZymes Technologies ASA to Report Q3, 2020 Results on Oct 22, 2020ArcticZymes Technologies ASA announced that they will report Q3, 2020 results on Oct 22, 2020
お知らせ • Aug 14ArcticZymes Technologies ASA to Report Q2, 2020 Results on Aug 19, 2020ArcticZymes Technologies ASA announced that they will report Q2, 2020 results at 7:00 AM, Central European Standard Time on Aug 19, 2020